
A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine
Kidney/Pancreas Transplant Program | SPLK Procedure | What to Expect | Indications and Contraindictions - Kidney/Pancreas | Indications and Contraindictions - Pancreas | Kidney/Pancreas Transplant Team
Patients with insulin dependent (Type 1, juvenile diabetes) diabetes who have end stage renal disease (ESRD) and require dialysis or expect to require dialysis in the next 12 months may be considered for SPK transplantation.
Patients may be evaluated for transplantation prior to the institution of dialysis. Patients are eligible for SPK transplantation if their creatinine clearance (Clcr) calculated by the Cockcroft-Gault formula is less than 20 ml/min. The Cockcroft-Gault formula for calculation of Clcr is now considered to be superior to actual measured creatinine clearance as determined by a 24-hour urine collection, due to inherent inaccuracies and collection difficulties.
The formula is as follows:
Clcr (ml/min) = (140-age)(wt. kg)
creatinine (mg/dl) x72
For women, the result is multiplied by 0.85
Patients referred for SPK transplantation, who are acceptable candidates by all criteria, are counseled about possible living donor kidney transplantation. Since there is an extreme shortage of cadaver kidneys in the United States and because living donor kidneys have a survival advantage over cadaver kidneys, diabetic patients with ESRD referred for SPK transplantation should consider living donor kidney transplant alone (LDKTA) followed by a pancreas after kidney (PAK) procedure.
The University of Maryland is the world leader in performing laparoscopic living donor nephrectomy, markedly reducing the cost and morbidity of living kidney donation. Furthermore, the University of Maryland has become the largest and most successful center in the United States in performing solitary pancreas transplants (PAK). Thus for patients referred for SPK transplantation, we offer the option of LDKTA plus a pancreas after kidney (PAK) procedure at a later date.
The LDKTA and PAK option carries equal pancreatic transplant success as SPK transplantation (see accompanying article; Bartlett ST, et al., Ann Surg,224:440-452,1996) combined with the added survival advantage of LDKTA. Patients presenting for SPK transplantation with no living donor options will wait for cadaveric SPK transplantation. Those with living donor options are offered the choice of cadaveric SPK or LDKTA plus PAK transplantation.
SPK Transplantation can be considered in Type 1 diabetic patients with ESRD when the patient has:
There are certain absolute contraindications to SPK transplantation:
Relative Contraindications to SPK transplantation: